Sunday February 18th 2018

Roche hits multiple sclerosis landmarks

Nature Reviews Drug Discovery 14, 739 (2015). doi:10.1038/nrd4780 Author: Asher Mullard Roche presented promising pivotal data for its ocrelizumab, including first Phase III evidence of efficacy for the treatment of primary progressive multiple sclerosis (PPMS). 10% of MS patients suffer from PPMS, a form of disease that is characterized by steady worsening of neurological function. There (Source: Nature Reviews Drug Discovery)

MedWorm Sponsor Message: Directory of the best January Sales in the UK. Find the best Christmas presents too.

Visit site:

Roche hits multiple sclerosis landmarks

Leave a Comment

More from category

What side effects can result from interferon?
What side effects can result from interferon?

Interferon is used to treat several health conditions, but it has a range of side effects. We look at how these vary in [Read More]

FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS
FDA Clears Higher-Dose Glatopa Generic for MS FDA Clears Higher-Dose Glatopa Generic for MS

Glatopa 40 mg/mL joins already-approved Glatopa 20 mg/mL, a glatiramer acetate generic for treatment of relapsing forms [Read More]

DIY faecal transplants carry risks including HIV and hepatitis, warn experts
DIY faecal transplants carry risks including HIV and hepatitis, warn experts

Faecal transplants have been used in medical settings to tackle superbugs, but following YouTube videos at home is too [Read More]

High blood pressure drug may also help prevent onset of type 1 diabetes
High blood pressure drug may also help prevent onset of type 1 diabetes

A drug commonly used to control high blood pressure may also help prevent the onset of type 1 diabetes in up to 60 [Read More]

Eye and balance exercises may ease multiple sclerosis symptoms
Eye and balance exercises may ease multiple sclerosis symptoms

Reuters Health - People with multiple sclerosis who do balance and eye movement exercises may feel steadier on their [Read More]